OncoPanCure Therapeutics has officially launched its Family, Friends & Fools (FFF) investment round to support the next stage of preclinical development of OPC080, its innovative drug candidate for pancreatic cancer. Founded in July 2026 as a biotechnology spin-off emerging from…
Barcelona, September 9, 2026 OncoPanCure S.L. today announced the licensing agreement with IQS School of Engineering – Universitat Ramon Llull and Xenopat S.L. for OPC080, OncoPanCure’s lead therapeutic candidate for the treatment of pancreatic cancer.The agreement grants OncoPanCure the rights…
Years of collaborative research have laid the foundations for OncoPanCure Therapeutics While OncoPanCure Therapeutics was only recently incorporated, the scientific journey behind its lead candidate, OPC080, began several years ago. The project originated from a multidisciplinary collaboration between researchers at IQS…
OncoPanCure SL launches to develop a first-in-class therapy for pancreatic cancer OncoPanCure Therapeutics is proud to announce its official incorporation as a biotechnology company dedicated to developing innovative therapies for pancreatic cancer, one of the most aggressive malignancies and one…
